-+ 0.00%
-+ 0.00%
-+ 0.00%
Cardiff Oncology Gets FDA Fast Track Designation for Onvansertib Combination in First-Line RAS-Mutated Colorectal Cancer
Share
Listen to the news
Cardiff Oncology Gets FDA Fast Track Designation for Onvansertib Combination in First-Line RAS-Mutated Colorectal Cancer
  • Cardiff Oncology received FDA Fast Track designation for onvansertib with FOLFIRI/bevacizumab as a first-line treatment for adults with KRAS- or NRAS-mutated metastatic colorectal cancer.
  • Already reported results from the ongoing randomized Phase 2 CRDF-004 trial showed higher tumor response rates than FOLFIRI/bevacizumab alone.
  • As of September 28, 2026, median progression-free survival remained unreached in the proposed Phase 3 regimen, compared with standard-of-care treatment.
  • A registrational trial is planned for the combination.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611160700PRIMZONEFULLFEED9878032) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending